Kamada Ltd. Submits U.S. Biologics License Application for the First Liquid, Ready to Use AAT for the Treatment of Alpha-1 Antitrypsin Deficiency

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA) – a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that it has submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for its lead clinical candidate, intravenous alpha-1 antitrypsin (“AAT-IV”), for the treatment of Alpha-1 Antitrypsin Deficiency.